News Pfizer finally decides not to split up company Company will remain as one, but Read keeps his options open
News Unjustified price rises will stop, promises Allergan chief Says 'outlier' companies have 'violated' social contract
Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.